Gynera 21 tablets

Tradename

Gynera

Compound:

Each tablet contains:

gestodene 0.075 mg

ethinylestradiol 0.03 mg

Excipients: sodium calcium edetate, lactose monohydrate, corn starch, povidone 25, magnesium stearate.

Properties

Combined oral hormonal contraceptive.

The gestagenic component is a derivative of 19-nortestosterone — gestodene, which is superior in strength and selectivity of action not only to the natural hormone of the corpus luteum progesterone, but also to other synthetic gestagens (for example, levonorgestrel). Due to its high activity, gestodene is used in low dosages, in which it does not exhibit androgenic properties and has practically no effect on lipid and carbohydrate metabolism.

The estrogenic component of the combination is ethinyl estradiol, a synthetic analogue of the follicular hormone estradiol, which, together with the corpus luteum hormone, participat in the regulation of the menstrual cycle.

Indications

Oral contraception.

Method of administration and dosage:

Oral tablets.

Contraindications

Presence of risk factors for venous thromboembolism; the presence of risk factors for the development of arterial thromboembolism; severe liver disease

(including history) before normalization of liver function indicators; liver tumor (including a history); severe chronic renal failure or acute renal failure; known or suspected hormonedependent malignant tumors (including genitals or breast); bleeding from the vagina of unclear etiology; pregnancy; lactation period (breastfeeding).

Precautions:

Side effects

From the side of the cardiovascular system: arterial hypertension; rarely — arterial and venous thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism); very rarely — arterial or venous thromboembolism of the hepatic, mesenteric, renal, retinal arteries and veins.

From the senses: hearing loss due to otosclerosis.

From the reproductive system: acyclic bleeding / spotting from the vagina, amenorrhea after discontinuation of the drug, changes in the state of vaginal mucus, development of inflammatory processes in the vagina, candidiasis, tension, pain, enlargement of the mammary glands, galactorrhea.